Transaction · 0001231919-26-001156

Mpm Bioventures 2018, L.P.

MPM BIOVENTURES 2018, L.P., 10%, reported an open-market or private sale at Entrada Therapeutics, Inc. involving 38500.000000 shares for an estimated $273735.00. Reported holdings after the transaction were 4106452.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
TRDAEntrada Therapeutics, Inc.
Trade date
Sep 04, 2026
Filing date
Sep 09, 2026
View on SEC Insider profile
Estimated value-$273kShares × reported price
Shares traded38.5k$7.11 per share
Holdings after4.10MIndirect · See Footnote
% of reported position traded0.93%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,144,952 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TRDA price since this filing

Daily closing prices, with the filing date and available return windows
TRDA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago -1.5%1d ago +0.8%
Returns since7d -3.1%30d -20.3%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001231919-26-001156
Common Stock
Transaction date
Sep 04, 2026
Filed Sep 09, 2026, 11:24 PM · 5d delay
Shares
38,500 sh
$7.11 per share
Estimated value
-$273k
Computed from shares × price
Holdings after
4,106,452 sh
Indirect · See Footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Repeat Seller
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
    Read the scoring methodology

    Signed filing-only points, not a probability or expected return. Version v1.

    Reported relationships & other filings

    Form 4 relationship flags and nearby filing context

    Reported roles

    No officer title

    Officer NoDirector No10% YesOther No
    Footnotes & amended
    1. F1

      The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014")…

    2. 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC")…

    3. partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2…

    4. manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

    5. F2

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

    6. (3 footnotes)

      number of shares sold at each separate price within the range set forth in this Form 4.

    7. F3

      The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

    8. F4

      Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

    9. F5

      The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

    10. F6

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

    11. F7

      The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

    12. F8

      The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

    13. F9

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

    14. F10

      The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

    Original filing · 0001231919-26-001156
    Related transactions

    0 other transactions

    Same SEC filing
    Recent company activity

    0 recent txs

    TRDA